The Immune Assessment Laboratory is an integral member of the NIH Cancer Moonshot initiative, CIMAC (Cancer Immune Monitoring and Analysis Center). Our expertise in mass cytometry contributes significantly to NCI-sponsored clinical trials nationwide.
As experts in Human Immune Monitoring for clinical trials, we collaborate with investigators at the Dana-Farber Cancer Institute and its affiliated partners, as well as external sites. Our primary mission is to establish mechanistic and biomarker endpoints for clinical studies. We bring forth our expertise to design and develop assays specifically tailored for biomarkers discovery.
Operating in a GLP quality-controlled and HIPAA compliant setting, IAL provides complete biobanking services: collection of blood, tissue and stool samples from patients participating in over 50 clinical trials.
Empowered by cutting-edge technologies, IAL specializes in delivering sophisticated solutions for the detection of soluble biomarkers. We proudly offer state-of-the-art Luminex and OLINK services, providing unparalleled accuracy and reliability in biomarker analysis.
Our comprehensive mass cytometry and spectral flow cytometry end-to-end solutions services are meticulously designed to unravel cellular phenotypes with precision and efficiency.
At IAL, we are committed to leveraging advanced technologies to meet the evolving demands of biomarker detection and cellular phenotyping. If you have any inquiries or specific requirements, please do not hesitate to reach out. We look forward to contributing to your research and analytical needs.